MYmAb Biologics 获得 GVPD 130 万令吉用于组织微阵列开发

August 2024: We are excited to announce that MYmAb Biologics Sdn. Bhd. has been awarded a generous RM 1.3 million under the prestigious Grant for High Value-Added Product Development (GVPD). This award, facilitated by the Ministry of Investment, Trade and Industry (MITI) Malaysia, is a major step in advancing our cutting-edge tissue microarray (TMA) technology and expanding our offerings in histopathology services.

This grant will enable MYmAb Biologics to accelerate the development of innovative, high-quality products aimed at improving research outcomes and offering new solutions to the scientific community.

What is the Grant for High Value-Added Product Development (GVPD)?

The GVPD is a funding initiative by the Malaysian government, designed to support businesses that develop and commercialise high-value-added products. Administered by MITI Malaysia, and monitored by Malaysian Industrial Development Finance (MIDF), this grant encourages innovation in industries that have a significant potential for national economic growth. By supporting companies like MYmAb Biologics, the GVPD ensures that businesses are able to compete at an international level.
With a focus on products that enhance value and drive innovation, the GVPD fosters the development of technologies that can positively impact various industries—making it an essential funding avenue for businesses aiming to transform their fields.

GVPD is applicable for:

The Grant for High Value-Added Product Development is particularly relevant for businesses involved in:
Biotechnology and Life Sciences: Innovators in biomedical research, like MYmAb Biologics, who are developing advanced technologies for healthcare and research.

  • Healthcare Solutions: Companies creating innovative healthcare products and diagnostic tools.
  • High Value-Added & Complex Product Manufacturing: Producers focusing on high-tech manufacturing and creating products with improved performance and value.
  • Research and Development: Organisations invested in R&D activities that generate new knowledge and solutions.
    This grant helps businesses enhance their competitive edge and contribute to Malaysia’s broader vision of being a hub for innovation and high-tech development.

How MYmAb Biologics Plans to Use the 
RM 1.3 Million Grant

With this GVPD grant, MYmAb Biologics aims to enhance its tissue microarray offerings and further our efforts in histopathology. Our company specialises in providing top-tier tissue microarray solutions, enabling researchers and clinicians to perform large-scale analysis in an affordable and efficient way.

This grant will allow us to:

  • Develop new, high-quality TMA products.
  • Enhance our digital pathology services to support researchers worldwide.
  • Expand our histopathology services which include H&E and IHC staining,  ensuring accuracy and reliability for research institutions.

We are committed to continuously improving our products and services, ensuring that we remain a trusted partner in cancer research and diagnostic development.

结论

The RM 1.3 million grant from the Grant for High Value-Added Product Development is a testament to MYmAb Biologics’ dedication to innovation in tissue microarray and histopathology. This support will enable us to push the boundaries of research and offer cutting-edge solutions to the scientific community, both in Malaysia and globally.

At MYmAb Biologics, we take pride in providing advanced, reliable, and affordable solutions for researchers and businesses looking for tissue microarray products and histopathology services.
If you’re in need of histopathology services or high-quality tissue microarrays, don’t hesitate to reach out. Let’s work together to advance research and innovation! Contact us today to learn more about our products and services.

×